Study ID: ECOG E2511

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer


The purpose of this study is to establish the safety and determine the optimal dose of ABT-888 (veliparib) that will be safely combined with standard doses of the chemotherapy drugs, cisplatin and etoposide (CE). Participants in this study have been diagnosed with extensive stage small cell lung cancer (SCLSC). After determining the optimal dose of ABT-888, an additional randomized clinical study will be used to compare CE plus placebo versus CE plus veliparib in patients with previously untreated SCLC.

Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Small Cell Lung Cancer
Phase I/II


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list